Objective-Bone morphogenic protein 4 (BMP4) is involved in the development of endothelial dysfunction in hypertension.
B
one morphogenic protein 4 (BMP4), a member of BMPs belonging to the transforming growth factors-β superfamily, plays an essential role in embryonic development, cartilage formation, and bone mineralization. 1, 2 In the cardiovascular system, mutations or anomalies of BMPmediated signals are related with many vascular diseases, 3 including pulmonary hypertension, 4 ,5 cardiovascular calcification, 6 -8 stroke, 9 and type 2 diabetes mellitus. 10 As a proinflammatory cytokine, BMP4 can be induced under the oscillatory shear stress stimulation.
11 BMP4 is upregulated in vasculature of atherosclerosis and hypertension.
12 BMP4 impairs endothelium-dependent vasodilatation. 13 Noggin is a negative regulator in bone development and neuronal differentiation, which binds to and inactivates BMP4. 14, 15 Noggin improves endothelial function in hypertension, inhibits BMP4-induced hypertension in mice, and counteracts the proatherogenic effects of BMP4 in endothelial cells. 16 BMP4 is also upregulated by saturated free fatty acid or in obese mice. 17 However, the involvement of BMP4 in diabetic vascular dysfunction is less clear.
BMPs bind to 2 types of serine threonine kinase receptor: type I and type II. 18 BMP type I receptors can be divided into 2 subgroups: activin receptor-like kinase 3 (ALK3 or BMPR1a) and ALK6 (BMPR1b) group and the ALK1 and ALK2 group. 3 BMP4 interacts with ALK3/6 with much higher affinity to form a binding complex and to trigger the downstream signaling. 18 The activation of BMP4 signaling leads to Smad-dependent and Smad-independent pathways, including the activation of NADPH oxidases, which results in elevated production of reactive oxygen species (ROS), In type 2 diabetes mellitus, endothelial dysfunction is both the trigger and the hallmark of cardiovascular complications. Oxidative stress is one of the major factors that cause endothelial dysfunction in hyperglycemic conditions and insulin resistance. 21 Vascular expression of BMPs and Smad activation is enhanced by hyperglycemic stimulation in type 2 diabetic mice. 10 However, the role of BMP4 to mediate endothelial dysfunction is largely unknown. In the present study, we hypothesize that inhibition of BMP4 protects against endothelial dysfunction in db/db diabetic mice through limiting ROS production in endothelial cells and thus increases nitric oxide (NO) bioavailability in blood vessels.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Inhibition of BMP4 In Vivo Improves Endothelial Function of db/db Mice
Acetylcholine-induced endothelium-dependent relaxations (EDRs) in db/db mouse aortae were diminished compared with those in db/m + mouse aortae. Noggin infusion to db/db mice restored the impaired EDRs in both aortae ( Figure 1A and 1B) and mesenteric arteries ( Figure 1C ). By contrast, sodium nitroprusside (SNP)-induced endothelium-independent relaxations were unchanged in the 3 groups ( Figure (Figure 1D ), whereas endothelium-independent relaxations were unaffected ( Figure IID in the onlineonly Data Supplement). In addition, flow-mediated dilatation in the second-order mesenteric arteries was evoked by creating a pressure difference of 20 mm Hg that equals an initial shear stress of ≈15 dynes/cm 2 . Flow-mediated dilatation was augmented in these resistance arteries of db/db mice with intravenous delivery of adenovirus BMP4-shRNA to suppress BMP4 expression ( Figure 1E ).
Ex Vivo Inhibition of BMP4 Restores EDRs
Apart from in vivo inhibition of BMP4, ex vivo suppression of BMP4 in tissue culture by 3 BMP4 inhibitors, chordin (200 ng/mL), follistatin (400 ng /mL), and noggin (100 ng/mL), also restored the impaired EDRs in isolated db/db mouse aortae ( Figure 2A ) without affecting SNP-induced relaxations ( Figure IIE in the online-only Data Supplement). Moreover, 48-hour treatment with high glucose (30 mmol/L) attenuated EDRs in aortae from C57BL/6 mice, which was reversed by cotreatment with noggin and chordin, as well as ROS scavenger tiron plus diethyldithiocarbamate ( Figure 2C ). By contrast, relaxations to SNP were comparable in different groups ( Figure IIF in the online-only Data Supplement).
Ex vivo 48-hour exposure to adenovirus BMP4-shRNA augmented EDRs in db/db mouse aortae ( Figure 2B ). Ex vivo adenovirus BMP4-shRNA transduction also restored EDRs that were impaired by high glucose in C57BL/6 mouse aortae ( Figure 2D ). Neither scramble nor BMP4-shRNA adenovirus affected EDRs in C57BL/6 mouse aortae ( Figure IIH in the online-only Data Supplement).
Inhibition of BMP4 Reduces ROS Generation in Endothelial Cells
The ROS levels measured by dihydroethidium (DHE) fluorescence were elevated in aortae from db/db mice compared with those from db/m + . Noggin infusion reduced the ROS production in db/db mouse aortae ( Figure 3A and 3B). Ex vivo treatment with noggin, chordin, or follistatin all reduced ROS accumulation in db/db mouse aortae ( Figure 3E and 3F) . Figure 3G and 3H shows that the elevated ROS generation in endothelial cells en face of db/db mouse aortas was reduced by treatment with the 3 BMP4 inhibitors.
In vivo BMP4-shRNA adenovirus transduction reduced DHE fluorescence intensity in db/db mouse aortic endothelial cells ( Figure 3C and 3D) . The similar results were also obtained in both cross-sections and endothelial cells in situ in db/db mouse aortic rings, which were treated with BMP4-shRNA adenovirus ex vivo ( Figure 3I ; Figure IV in the online-only Data Supplement). Finally, both BMP4-shRNA adenovirus transduction and noggin treatment reversed highglucose-stimulated increase in the content of superoxide anions in C57BL/6 mouse aortae ( Figure 3J ).
In human umbilical vein endothelial cells and mouse aortic endothelial cells, intracellular ROS were measured using CM-H 2 DCFDA (DCF) dye. High-glucose treatment increased DCF signal, which was reversed by noggin (100 ng/mL), chordin (200 ng/mL), and follistatin (400 ng/mL), as well as ROS scavenger tempol (100 μmol/L) and putative nicotinamide adenine dinucleotide phosphate oxidase inhibitor diphenylene iodonium (0.1 μmol/L; Figure V and VIIB in the online-only Data Supplement). 
Silencing ALK3 Improves Endothelial Function in db/db Mice
To illustrate the role of BMP4 receptor ALK3 in endothelial dysfunction in diabetic mice, ALK3 was silenced using 2 ALK3 shRNAs (shRNA-1 and shRNA-3) via lentiviral transfection and confirmed by Western blotting data ( Figure 4B ). ALK3 silencing inhibited the ability of BMP4 to impair EDRs in C57BL/6 mouse aortae ( Figure 4A ) and reduced 
Noggin Reduces BMP4 Upregulation in db/db Mice
Compared with db/m + mouse aortae, db/db mouse aortae expressed higher levels of BMP4 and this increase was reversed by noggin infusion ( Figure 5A ). The immunohistochemical images of the walls of aortae show that BMP4 expression upregulated in both endothelial and vascular smooth muscle cells was inhibited by ex vivo treatment with noggin in db/db mouse aortae ( Figure 5B ). Likewise, immunofluorescence staining shows that noggin reduced the BMP4 expression in endothelial cells en face of db/db mouse aortae ( Figure 5C and 5D ). In addition, high glucose increased the BMP4 expression and noggin inhibited this effect in ex vivocultured C57BL/6 mouse aortae ( Figure 5E ). Furthermore, high glucose increased the BMP4 expression in mouse aortic endothelial cells in a time-dependent manner ( Figure IXA in the online-only Data Supplement) and noggin reversed this effect of high glucose ( Figure 5F ).
Discussion
The present study demonstrates that BMP4 mediates endothelial dysfunction in db/db mice. The inhibition of BMP4 reduces oxidative stress, increases NO bioavailability, and improves endothelial function in diabetic mice and in cultured endothelial cells under hyperglycemic stimulation. BMP4 receptor 1a (ALK3) plays a crucial role in mediating BMP4 to induce oxidative stress and endothelial dysfunction.
BMP4 is involved in the development of endothelial dysfunction in hypertension, 13, 19 atherosclerosis, 22, 23 and vascular calcification.
24 BMP4 is also an upstream regulator in the process of diabetic nephropathy induced by streptozotocin in BMP4-overexpressing mice. 25 Previous studies showed that high glucose or free fatty acids upregulate BMP4 in endothelial cells, 10, 17 indicating that BMP4 may be important in endothelial dysfunction associated with diabetes mellitus and hyperglycemia. However, the role of BMP4 in regulating endothelial function of type 2 diabetes mellitus is largely unclear. The present study shows that functional inhibition of the BMP4 signaling by either BMP4 antagonists or RNAi or silencing of ALK3 restores the impaired endothelial function in db/db mice.
The present results show that noggin infusion augmented endothelial function in both conduit and resistance arteries from db/db mice. Improved endothelial function in resistance vessels may contribute to the blood pressure reduction after noggin infusion. However, noggin infusion did not alter insulin tolerance or insulin-induced relaxations in db/db mouse aortae, suggesting that the improvement of endothelial function by BMP4 inhibition is unlikely to be attributed to the change of insulin sensitivity. More importantly, suppression of BMP4 by inhibitors or adenovirus shRNA directly improved endothelial function in isolated db/db mouse aortae and C57BL/6 mouse aortae treated with high glucose in ex vivo culture, indicating that noggin or BMP4 silencing produces a direct beneficial effect on the arteries, thus suggesting a positive role of BMP4 in vascular dysfunction in diabetic mice.
BMP4 induces oxidative stress and subsequent upregulation of proinflammatory cytokines and adhesion molecules, in response to oscillatory shear stress, or stimulation of cardiovascular risk factors such as free fatty acid and hyperglycemia. 10, 17, 26 BMP4-induced ROS production is mediated through the activation of Nox1, Nox2, and Nox4. 17, 19, [26] [27] [28] Here, we showed that ROS production in the aortic endothelium of db/db mice was inhibited by BMP4 inhibitors, BMP4 silencing, and ROS scavengers, as well as in the endothelial cells exposed to high glucose.
The expression of BMP4 is higher in db/db mouse aortae compared with that from db/m + , similar to the previous studies showing high-glucose-induced BMP4 upregulation in several cell types. 10, 29, 30 We also observed that noggin reduced BMP4 expression both in vivo and in vitro. The inhibitory effect of noggin on BMP4 expression is likely to be attributable to the suppression of NADPH oxidase activity. Knockdown of ALK3 improved EDRs in isolated db/db mouse aortae, indicating active interaction between endogenous BMP4 and ALK3 in arteries of diabetic mice. BMP4 binds to the BMP receptors 31, 32 (ALK2, ALK3, and ALK6) and forms the ligand-receptor complex 33 to exert its cellular actions. BMP4-activated ALK3 signaling mediates endothelial dysfunction induced by BMP4 and promotes remodeling of pulmonary vasculature during hypoxia. 5, 13 ALK3 is also involved in the development of obesity 34 and cardiovascular disease. 35 The present results suggest that ALK3 plays a more significant role to mediate BMP4-induced harmful effect on endothelial cells as ALK3 silencing reverses BMP4-stimulated ROS production in cultured endothelial cells. Despite a complete inhibition of BMP4-stimulated ROS elevation in endothelium en face of intact mouse aortae, ALK3 silencing only causes a partial reversal of BMP4-induced impairment of acetylcholine-induced relaxations in mouse aortae. Therefore, it is possible that other ALK isoforms may also play a contributory role in BMP4-impaired endothelial function in mouse arteries, which warrants further examination.
In summary, we elucidate the critical role of endothelial BMP4 and BMP4-induced oxidative stress in endothelial dysfunction of diabetic mice. Together with the existing evidence for the beneficial effect of BMP4 inhibition in atherosclerosis and hypertension, the present results add additional lines of new evidence supporting the importance of BMP4 signaling in diabetic vasculopathy. 
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